| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KCNA1 |
| Uniprot No | Q09470 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-154aa |
| 氨基酸序列 | MTVMSGENVDEASAAPGHPQDGSYPRQADHDDHECCERVVINISGLRFETQLKTLAQFPNTLLGNPKKRMRYFDPLRNEYFFDRNRPSFDAILYYYQSGGRLRRPVNVPLDMFSEEIKFYELGEEAMEKFREDEGFIKEEERPLPEKEYQRQVW |
| 预测分子量 | 22.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KCNA1重组蛋白的3篇代表性文献的简要概括(注：文献信息为模拟示例，实际引用需核实)：
1. **文献名称**：*Structural basis of KCNA1 voltage-gated potassium channel autoinhibition*
**作者**：Smith A, et al.
**摘要**：通过冷冻电镜解析了KCNA1重组蛋白的晶体结构，揭示了其电压敏感结构域的自抑制机制，为突变相关神经疾病的分子机制提供了结构基础。
2. **文献名称**：*Functional characterization of KCNA1 mutations in episodic ataxia using recombinant channels*
**作者**：Lee B, et al.
**摘要**：利用重组KCNA1蛋白进行电生理分析，发现特定突变(如R167M)导致钾电流减弱，阐明了突变引发发作性共济失调的功能缺陷机制。
3. **文献名称**：*High-yield expression and purification of KCNA1 in HEK293 cells for drug screening*
**作者**：Chen X, et al.
**摘要**：开发了一种高效重组KCNA1蛋白在HEK293细胞中的表达与纯化方法，验证其药理学活性，为靶向KCNA1的化合物筛选提供了技术平台。
如需具体文献，建议在PubMed或Web of Science中检索关键词“KCNA1 recombinant protein”或“KCNA1 expression”获取最新研究。
KCNA1. also known as Kv1.1. is a voltage-gated potassium channel protein encoded by the KCNA1 gene. It plays a critical role in regulating neuronal excitability by controlling the flow of potassium ions across cell membranes, contributing to action potential repolarization and signal damping in the nervous system. Dysfunction of KCNA1 is linked to neurological disorders such as episodic ataxia type 1 (EA1) and epilepsy, often caused by mutations that alter channel gating or trafficking.
Recombinant KCNA1 protein is engineered in vitro using expression systems (e.g., Escherichia coli, mammalian cells) to produce purified, functional forms of the channel for research. These systems enable precise study of its structure, biophysical properties, and interactions with drugs or cellular partners. The recombinant protein typically retains key domains, such as the voltage-sensing region and pore-forming segments, allowing researchers to investigate mechanisms underlying channelopathies or screen potential therapeutics.
Applications include electrophysiological studies to characterize mutant variants, structural biology (e.g., cryo-EM) to resolve 3D conformations, and antibody development for diagnostic tools. Recombinant KCNA1 also aids in exploring its role in autoimmune conditions, where autoantibodies target potassium channels. By providing a controlled, scalable source of the protein, it accelerates mechanistic insights and drug discovery for KCNA1-related diseases.
Overall, KCNA1 recombinant protein serves as a vital tool for decoding channel physiology, disease pathways, and therapeutic interventions in neurology.
×
